AEON News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AE

Volume

239.47K

Next Earnings

November 13th

Loading chart

AE

AEONAEON Biopharma, Inc.

AEON

Pay with—

Available Balance0.00

AE

Mkt Cap

$12.1M

Volume

239.47K

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

Bitget Launchpool adds AEON (AEON) with 1.1M in Token RewardsBitget, the world's largest Universal Exchange, announced the listing of AEON (AEON), a crypto settlement middleware enabling digital asset payments to real-world merchants. Spot trading for AEON/USDT begins July 27, 2026, with a Launchpool campaign offering 1,166,666 AEON in rewards through BGB and AEON token locking.GlobeNewswire Inc. · Jul 27, 2026

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache SocietyAEON Biopharma announced presentation of analytical and functional data supporting biosimilarity of ABP-450 to BOTOX® at the American Headache Society meeting. The data demonstrates highly similar biological activity through multiple analytical approaches, with LC-MS peptide mapping showing 93%-99% sequence coverage and LD50 potency assay results falling within equivalence criteria established from BOTOX® reference results.GlobeNewswire Inc. · Jun 4, 2026

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711AEON Biopharma announced the appointment of John Bencich as Chief Financial Officer on April 2, 2026, granting him 754,717 RSUs and 235,849 PSUs as inducement awards. The PSUs vest upon the company regaining NYSE American listing compliance. AEON is developing ABP-450, a biosimilar to BOTOX®, targeting the $3 billion U.S. therapeutic neurotoxin market.GlobeNewswire Inc. · Apr 3, 2026

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711AEON Biopharma announced the grant of 392,158 restricted stock units to newly hired non-executive employees on December 11, 2025, under its 2025 Inducement Incentive Plan. The RSUs vest over four years with 25% vesting annually. The company continues development of ABP-450, a BOTOX biosimilar targeting the $3 billion U.S. therapeutic neurotoxin market.GlobeNewswire Inc. · Dec 19, 2025

Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsightThe migraine therapeutics market is experiencing strong growth, with over 30 companies developing innovative treatments targeting migraine through advanced therapies like CGRP inhibitors and gepants, supported by improved diagnostic recognition and patient awareness.GlobeNewswire Inc. · Dec 2, 2025

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public OfferingAEON Biopharma, a clinical-stage biopharmaceutical company, announced the closing of a $20 million public offering. The company plans to use the proceeds for general corporate purposes and working capital.Benzinga · Jan 7, 2025

AEON Biopharma, Inc. Announces Launch of Proposed Public OfferingAEON Biopharma, a clinical-stage biopharmaceutical company, announced a public offering of shares and warrants to raise funds for general corporate and working capital needs.GlobeNewswire Inc. · Jan 4, 2025

Why Match Group Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - BenzingaMatch Group shares jumped 8% in pre-market trading after Starboard Value took a stake of over 6.5% in the company and is advocating for a potential sale. Several other stocks also saw significant pre-market movement.Benzinga · Jul 16, 2024

Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a TurnaroundAEON Biopharma, Inc. (AEON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.Zacks Investment Research · May 29, 2024

AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerAEON Biopharma, Inc. (AEON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.Zacks Investment Research · May 9, 2024

to start trading

AE

AEONAEON Biopharma, Inc.

AEON

Pay with—

Available Balance0.00

Your PositionYou don't own any AEON yet.

Related Tickers

Earnings